CDC PrEP Clinical Practice Guideline and Strategies for Ending the HIV Epidemic in the US
You must Login or Create Account in order to register for this event
Presenters
Demetre C. Daskalakis, MD, MPH
Centers for Disease Control and Prevention
Dawn K. Smith, MD, MS, MPH
Centers for Disease Control and PreventionModerator
Raphael J. Landovitz, MD, MSc
University of California Los AngelesOverview
Assessment of Needs
This webinar will provide a concise summary of the latest 2021 update to the Centers for Disease Control and Prevention’s preexposure prophylaxis (PrEP) guidelines. The guidelines include new clinical guidance for the prescription of cabotegravir injections as PrEP for sexually active adults, which was approved by the US Food and Drug Administration in December 2021. Additionally, it provides key changes in testing and monitoring patients who are starting or taking PrEP.
This webinar is part 1 of a 2-part webinar series on the updated PrEP guidelines. Part 2 will discuss the implementation of long-acting PrEP in a clinic, in a case-based panel discussion. Date and time to be announced.
Learning Objectives
At the end of this webinar, participants will be able to:
- Assess HIV trends, prevalence, and infection rates in the United States
- Explain the impact and status of PrEP for the HIV prevention goals of the Ending the HIV Epidemic initiative
- Describe updates to the latest PrEP guidelines, including new clinical guidance for the prescription of cabotegravir injections as PrEP
- Identify key changes in testing and monitoring patients who are starting or taking PrEP
- List strategies for identifying and engaging patients who could benefit from HIV prevention (eg, the syndemic approach and status neutral service delivery)
Registration
Who Should Attend
This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Tuesday, March 22, 2022, 9:00 AM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Presenters
Dr Daskalakis has no relevant financial affiliations with ineligible companies to disclose. (Updated 02/08/22)
Dr Smith has no relevant financial affiliations with ineligible companies to disclose. (Updated 02/08/22)
Moderator
Dr Landovitz has served on scientific advisory boards for Gilead Sciences, Inc, and Merck & Co, Inc. (Updated 9/20/21)
Planner/Reviewer
Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22)
Planner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 02/08/22)
CME Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
Nursing Credits
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
Pharmacy Credits
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-22-153-L02-P
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
PLATINUM SUPPORTERS
Gilead Sciences, Inc.
Merck & Co, Inc
ViiV Healthcare
SILVER SUPPORTER
Janssen Therapeutics
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.